MedDay Pharmaceuticals is a biotechnology company developing new drugs targeting brain metabolism to treat diseases of the nervous system in areas of high unmet need. MedDay Pharmaceuticals S.A.S. is a biotechnology company developing drugs for the treatment of nervous system disorders.
MedDay is Paris based company, founded by Fr_d_ric Sedel and Guillaume Brion, identifies new therapeutic targets through cerebrospinal fluids metabolomic analysis.
In June 2015, MedDay and DSM announce a partnership to produce pharmaceutical grade D-Biotin to treat progressive multiple sclerosis.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/medday-pharmaceuticals” connections=”true” suffix=””]
MedDay has developed a SPECMET research platform in partnership with Assistance Publique Hopitaux de Paris (APHP) and Commissariat _ lEnergie Atomique (CEA). The SPECMET metabolomics platform screens cerebrospinal fluid from patients with CNS disorders to identify metabolic pathways that are disrupted.
March 2017, MedDay Boosts its Research platform by acquiring the health division of Profilomic SA . The acquisition will allow MedDay to significantly strengthen its existing metabolomics research platform, SPECMET, with the aim of expanding its pipeline of neurological disorder therapies.
In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested a total of 8 million in MedDay as Series A funding.
Recover your password.
A password will be e-mailed to you.